Continuous administration of PTH or high circulating PTH levels achieved in primary hyperthyroidism causes bone demineralization and osteopenia. Paradoxically, intermittent PTH administration promotes bone growth. The FDA has approved human recombinant PTH (1-34) for treating severe osteoporosis, and full-length PTH is also undergoing clinical trials.
ABSORPTION, FATE, AND EXCRETION
Pharmacokinetics and systemic actions of PTH (1-34) (teriparatide, forteo) are identical to those for endogenous PTH. Teriparatide is administered by once-daily subcutaneous injection of 20 xg into the thigh or abdomen. With this regimen, serum PTH levels peak at 30 minutes after the injection and decline to undetectable levels within 3 hours. Teriparatide is eliminated by nonspecific enzymatic mechanisms in the liver and kidney.
Was this article helpful?
Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...